Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjvNnhKSzVyPUCuNFAxPDV6IH7N NXPERmlWW0GQR1XS
ES4 NXLmN3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMECwOlU{KG6P MmK1V2FPT0WU
ACHN NEfablBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMECwPFg4KG6P MXrTRW5ITVJ?
KYSE-510 M3WwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPJd2VNUUN3ME2wMlAxODl5NTDuUS=> NVnMb5M6W0GQR1XS
EW-7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMECyOVghdk1? MnjVV2FPT0WU
BFTC-905 M2ruUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEC1NVUhdk1? MofBV2FPT0WU
KE-37 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXNNnBKSzVyPUCuNFA2PjFibl2= M3u1dHNCVkeHUh?=
SBC-5 NET3SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3fVFKSzVyPUCuNFA2PyCwTR?= NIjRXlhUSU6JRWK=
NKM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMEC3NFkhdk1? M1TEUnNCVkeHUh?=
RH-1 M1rEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mxbWlEPTB;MD6wNFcyQCCwTR?= MVzTRW5ITVJ?
ALL-PO MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HLW2lEPTB;MD6wNFg{KG6P NXnEdZR6W0GQR1XS
QIMR-WIL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW0TWM2OD1yLkCwPFk1KG6P NUTXOI8zW0GQR1XS
A375 M1G3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqyemxTUUN3ME2wMlAxQTl3IH7N M{fUSnNCVkeHUh?=
SIG-M5 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHBcI5XUUN3ME2wMlAyODRibl2= MXPTRW5ITVJ?
KGN M3nTcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEGwPEBvVQ>? MV\TRW5ITVJ?
EW-13 NVTKcJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETJS3NKSzVyPUCuNFEyOiCwTR?= MXTTRW5ITVJ?
NCI-SNU-1 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXIdZdKSzVyPUCuNFE3KG6P Mn32V2FPT0WU
PSN1 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW1TWM2OD1yLkCxOlUhdk1? NYDOdlEyW0GQR1XS
HUTU-80 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LSd2lEPTB;MD6wNVY3KG6P MoPGV2FPT0WU
EW-16 NY\nboFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEKzJI5O MVjTRW5ITVJ?
786-0 NFvkN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\DVGlEPTB;MD6wNlMhdk1? NVyzTpNqW0GQR1XS
ES1 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1yLkCyOlghdk1? M134S3NCVkeHUh?=
RKO M1\VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7OS45KSzVyPUCuNFI4QSCwTR?= NV3SfIFnW0GQR1XS
ESS-1 NIDRbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DQRmlEPTB;MD6wNlg3KG6P MVrTRW5ITVJ?
SK-UT-1 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEK5O{BvVQ>? MnPQV2FPT0WU
LB2241-RCC MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\XWnpmUUN3ME2wMlA{OThibl2= NXPSOlVxW0GQR1XS
CHL-1 NFPtbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XyT2lEPTB;MD6wN|I1KG6P NXfnOYVZW0GQR1XS
SW1783 NXTF[4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEOzOkBvVQ>? NXrDOYJ3W0GQR1XS
MEL-JUSO NWDISG5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrSUFNKSzVyPUCuNFM6OSCwTR?= NVn6VpJxW0GQR1XS
HT-29 NFvTblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXwdlZKSzVyPUCuNFQyOyCwTR?= NVThcZhbW0GQR1XS
SNG-M NFXXPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPJTWM2OD1yLkC0NlUhdk1? MVfTRW5ITVJ?
TE-15 NILDUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMES2OEBvVQ>? NUPi[m13W0GQR1XS
HOS M1\oUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3POXWlEPTB;MD6wOFghdk1? MljzV2FPT0WU
BB65-RCC M1;lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPkXJlKSzVyPUCuNFUyOiCwTR?= MV7TRW5ITVJ?
HCE-4 M{jwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLPRlJuUUN3ME2wMlA2Ojhibl2= MXHTRW5ITVJ?
MHH-ES-1 NX7Wb2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorOTWM2OD1yLkC1N|Ehdk1? MmLJV2FPT0WU
RPMI-7951 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174fmlEPTB;MD6wOVQyKG6P NWjQPW9uW0GQR1XS
IST-SL2 NWrFc5NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnvTWM2OD1yLkC1PFQhdk1? MmjiV2FPT0WU
CMK MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXEfGQ3UUN3ME2wMlA2QDZibl2= NGPrO5ZUSU6JRWK=
GR-ST NHrwUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH5S5JKSzVyPUCuNFU6PSCwTR?= MnOxV2FPT0WU
NALM-6 NXLZVWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ftU2lEPTB;MD6wOlIzKG6P MYfTRW5ITVJ?
RPMI-6666 NX\1TWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTNTWM2OD1yLkC2OVIhdk1? Mn\DV2FPT0WU
LC-2-ad MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwME[1N{BvVQ>? Moj6V2FPT0WU
ARH-77 M{PvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoezTWM2OD1yLkC3NVEhdk1? MXrTRW5ITVJ?
IST-MEL1 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEeyOkBvVQ>? M2nyO3NCVkeHUh?=
SW1710 NXXkN3J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XwbmlEPTB;MD6wO|UyKG6P M4jHU3NCVkeHUh?=
DEL MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD1yLkC4PFchdk1? NH\ScoRUSU6JRWK=
AGS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PmNmlEPTB;MD6wPVAzKG6P MWjTRW5ITVJ?
NCI-H2122 NIXvSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEm0OkBvVQ>? NYnQbIxzW0GQR1XS
HSC-4 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPiS5BKUUN3ME2wMlExOiCwTR?= Ml7xV2FPT0WU
AM-38 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qwRmlEPTB;MD6xNlEhdk1? NXHYfZNvW0GQR1XS
769-P M4ewOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfpW5FSUUN3ME2wMlEzOyCwTR?= M4[0OHNCVkeHUh?=
RT-112 NHHw[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[zTWM2OD1yLkGyO{BvVQ>? NGDIUYxUSU6JRWK=
MCF7 M3jKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMUO2JI5O NXfK[GRtW0GQR1XS
IGROV-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf5N5RKSzVyPUCuNVQ2KG6P MnvWV2FPT0WU
OCI-AML2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XFWWlEPTB;MD6xOFchdk1? NIPj[m1USU6JRWK=
NCI-H1299 M2nHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrYcXVyUUN3ME2wMlE2PyCwTR?= NEGyVYJUSU6JRWK=
A431 M1XDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\yTWM2OD1yLkG4N{BvVQ>? M1vBV3NCVkeHUh?=
SW982 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlznTWM2OD1yLkKxN{BvVQ>? MUTTRW5ITVJ?
BB30-HNC NFzmN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPjV4hKSzVyPUCuNlMyKG6P MVTTRW5ITVJ?
ACN M3LUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXBTodKSzVyPUCuNlQ1KG6P NInrdotUSU6JRWK=
647-V M3XmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMkS4JI5O NX;vN2U1W0GQR1XS
SK-PN-DW Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMk[2JI5O NVPrcIxpW0GQR1XS
LCLC-97TM1 M2PJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ITWM2OD1yLkK2O{BvVQ>? MVPTRW5ITVJ?
LB1047-RCC NGfrVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\RTWM2OD1yLkK2PUBvVQ>? Ml60V2FPT0WU
A2780 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Tyd2lEPTB;MD6yO{BvVQ>? MnfqV2FPT0WU
C-33-A NVHuNlE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nSUGlEPTB;MD6yO|Mhdk1? MmnmV2FPT0WU
NCI-H2228 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm0TWM2OD1yLkOxOEBvVQ>? M1TGR3NCVkeHUh?=
TE-5 NGXZenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fDR2lEPTB;MD6zNVYhdk1? Ml7VV2FPT0WU
HC-1 NUSzeVRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ftPGlEPTB;MD6zNlchdk1? MUHTRW5ITVJ?
SK-MES-1 M2\Ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwM{K4JI5O NELmbFlUSU6JRWK=
NCI-H1355 M1LBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwM{ixJI5O M1zIOHNCVkeHUh?=
YKG-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu4V5VKSzVyPUCuOFE6KG6P NEXabHlUSU6JRWK=
RS4-11 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HOcGlEPTB;MD60N|Mhdk1? MWfTRW5ITVJ?
Daoy M1HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPWclVKSzVyPUCuOFU3KG6P M3nXU3NCVkeHUh?=
A3-KAW NI\Mem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjXTWM2OD1yLkW1NUBvVQ>? Mnf5V2FPT0WU
SK-MEL-30 NWTsZWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwNUW0JI5O NGe5WJNUSU6JRWK=
U031 NWTUWYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPDbWlKSzVyPUCuOVY2KG6P M2jaS3NCVkeHUh?=
SK-LMS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrJUnVHUUN3ME2wMlU4QCCwTR?= MYrTRW5ITVJ?
ES6 NWK4ZVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPlO2g2UUN3ME2wMlU5PiCwTR?= NUe3OZZXW0GQR1XS
EoL-1-cell NUfE[ld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{npcGlEPTB;MD62NVYhdk1? M{PLR3NCVkeHUh?=
NCI-H2009 NHTLeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fUfWlEPTB;MD62NVkhdk1? MojGV2FPT0WU
A4-Fuk MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K5XWlEPTB;MD62NlYhdk1? NHXTVI5USU6JRWK=
KYSE-270 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S5WGlEPTB;MD62N|Qhdk1? NY[wRWxNW0GQR1XS
SK-LU-1 NUXLS|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfIO2g3UUN3ME2wMlY2PSCwTR?= NILpSHlUSU6JRWK=
SW872 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnBbJVKSzVyPUCuO|Y2KG6P MknDV2FPT0WU
ES8 M4rrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjCR5FKSzVyPUCuO|ghdk1? NXHZeJhsW0GQR1XS
G-402 M4j5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nMNmlEPTB;MD63PFQhdk1? MkXQV2FPT0WU
ATN-1 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwOEC3JI5O MkXuV2FPT0WU
DoTc2-4510 NIP5epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwOUCxJI5O MV7TRW5ITVJ?
MES-SA MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknQTWM2OD1yLkmwOUBvVQ>? MoDOV2FPT0WU
SF268 M4HUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwOUK3JI5O MnmxV2FPT0WU
SF539 NHTTWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMEKgcm0> MoLTV2FPT0WU
NB69 NFfwRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsVFNKSzVyPUGuNFUhdk1? MnrJV2FPT0WU
8505C M3HvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwME[gcm0> MmTwV2FPT0WU
CAL-12T MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfwTWM2OD1zLkC4JI5O MX3TRW5ITVJ?
BHY NHm5VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfRWmlyUUN3ME2xMlE1KG6P NIj6XIlUSU6JRWK=
LB647-SCLC M{T0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXncXB3UUN3ME2xMlE5KG6P NWTyc2hMW0GQR1XS
CAL-62 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XJcGlEPTB;MT6yNkBvVQ>? M3XKNHNCVkeHUh?=
MEG-01 M3;6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7WTWM2OD1zLkK3JI5O MmH4V2FPT0WU
MG-63 M4fQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwM{Ogcm0> NWnkUZJoW0GQR1XS
SW620 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HRT2lEPTB;MT6zOUBvVQ>? NXK4SFFwW0GQR1XS
A388 NGLHTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFZZNKSzVyPUGuN|Yhdk1? M{CwZXNCVkeHUh?=
BCPAP MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Oze2lEPTB;MT60OUBvVQ>? M3jldnNCVkeHUh?=
P30-OHK NILWU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\4TlhKSzVyPUGuOFYhdk1? NVW2SpZjW0GQR1XS
Ca9-22 M2fNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jLc2lEPTB;MT61OEBvVQ>? NIjXdXZUSU6JRWK=
VMRC-RCZ NXvYZlZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjKZVNKSzVyPUGuOVQhdk1? NX7JNW5LW0GQR1XS
LOXIMVI NFm5cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrXZpJmUUN3ME2xMlYhdk1? MUfTRW5ITVJ?
L-540 Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfBTWM2OD1zLk[gcm0> MXjTRW5ITVJ?
NTERA-S-cl-D1 NH\HRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDWdWVKSzVyPUGuOlQhdk1? NEHKfpZUSU6JRWK=
MFH-ino NE\6SotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPB[JpKSzVyPUGuOlYhdk1? M3ru[HNCVkeHUh?=
Calu-6 NEP0NVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaTWM2OD1zLkezJI5O NF7CVVRUSU6JRWK=
HEL NXTuNZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnlcXJKSzVyPUGuO|khdk1? NXj0e3NUW0GQR1XS
CAL-33 NGi3codIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwOEmgcm0> NUi0bIdrW0GQR1XS
HSC-3 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zHS2lEPTB;MT65NUBvVQ>? NV;0WYtJW0GQR1XS
KU812 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwOUGgcm0> NYLod5l7W0GQR1XS
EB2 NETrW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fNXGlEPTB;Mj6wNUBvVQ>? NG\FcI9USU6JRWK=
SR M4D2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJwMUKgcm0> Ml\TV2FPT0WU
NCI-H2087 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\k[W17UUN3ME2yMlE1KG6P MX;TRW5ITVJ?
H4 NHHOVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f6PWlEPTB;Mj6xPEBvVQ>? NFHve4xUSU6JRWK=
EW-1 M2WzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrpTWM2OD1{LkKyJI5O Ml;mV2FPT0WU
MC-IXC NV3kZ2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojVTWM2OD1{LkK2JI5O M2LXenNCVkeHUh?=
NCI-H727 NWiwc|R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLkSZZsUUN3ME2yMlUyKG6P NEDnOmdUSU6JRWK=
MRK-nu-1 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwNUegcm0> NEPROW1USU6JRWK=
COLO-668 M1rUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwNk[gcm0> MXzTRW5ITVJ?
CGTH-W-1 NWnafIZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK3TWM2OD1{LkeyJI5O MkfUV2FPT0WU
CHP-212 NVjvZph7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwN{Wgcm0> MnKxV2FPT0WU
GI-1 M2TONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLOWlgyUUN3ME2yMlc3KG6P M2WyR3NCVkeHUh?=
HCC1806 NUezTpBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7kTWM2OD1{LkmxJI5O Mlu5V2FPT0WU
HLE M3;GfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNibl2= MV7TRW5ITVJ?
HSC-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnoeXByUUN3ME2zMlA{KG6P NH;JOnFUSU6JRWK=
DMS-273 NVG2UmozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwMEegcm0> Ml;mV2FPT0WU
DU-4475 NVrMfGJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fTW2lEPTB;Mz6xOEBvVQ>? NEfUdItUSU6JRWK=
LXF-289 M4XHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTNTWM2OD1|LkOxJI5O NH23dmlUSU6JRWK=
PANC-03-27 NIPjc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NS2lEPTB;Mz61NUBvVQ>? MUfTRW5ITVJ?
GAMG NGLMVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jJOGlEPTB;Mz63OEBvVQ>? MXvTRW5ITVJ?
NCI-H522 NFfQ[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\TWoJoUUN3ME20MlM1KG6P NWPi[lVwW0GQR1XS
SW626 NGHMdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTvTWM2OD12LkS2JI5O MXXTRW5ITVJ?
HT-144 NVr6bnQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjpT5FqUUN3ME20MlkzKG6P NEHvdJNUSU6JRWK=
MEL-HO M{HwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXuTWM2OD13LkG2JI5O M2\5cnNCVkeHUh?=
BE-13 NWfoO5RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnBTWM2OD13LkKxJI5O MUjTRW5ITVJ?
VA-ES-BJ NY\qbY9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPK[3pKSzVyPUWuNlYhdk1? MYLTRW5ITVJ?
NCI-H441 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETLbmVKSzVyPUWuOkBvVQ>? M{jIS3NCVkeHUh?=
KP-4 NV\zNmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInaPG9KSzVyPUWuOlEhdk1? NFPXWGRUSU6JRWK=
LoVo NGPMNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fYdWlEPTB;NT63NUBvVQ>? NHrtdHBUSU6JRWK=
HT-1080 NVG4eoJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nydGlEPTB;NT64N{BvVQ>? MYHTRW5ITVJ?
GB-1 NYLsSWtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xud2lEPTB;NT64OEBvVQ>? MVTTRW5ITVJ?
IA-LM MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvNdXRxUUN3ME21MlkyKG6P NF:1dnZUSU6JRWK=
8-MG-BA MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfTTWM2OD13LkmzJI5O MUfTRW5ITVJ?
SK-HEP-1 NEfO[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjLTWM2OD14LkG0JI5O NUe5dpJ3W0GQR1XS
697 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETDXXhKSzVyPU[uNlUhdk1? NV\WcYxlW0GQR1XS
KYSE-450 NYj0c3BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXuTWM2OD14LkOyJI5O NHnPZY5USU6JRWK=
HCC2998 NVvIdJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jze2lEPTB;Nj6zOEBvVQ>? NFe2XoNUSU6JRWK=
HD-MY-Z MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LCdGlEPTB;Nj62PEBvVQ>? NIfZVnZUSU6JRWK=
OS-RC-2 NELiUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KxcGlEPTB;Nj62PEBvVQ>? NIfyNlNUSU6JRWK=
SF126 M32wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL5XIxKSzVyPUeuNFUhdk1? MYnTRW5ITVJ?
Ca-Ski MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2W45WUUN3ME23MlA6KG6P MXPTRW5ITVJ?
NCI-H358 M3j5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\E[JpKSzVyPUeuNVYhdk1? MXXTRW5ITVJ?
J82 NHfJNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXqfnhKSzVyPUeuOFEhdk1? NH\hZWJUSU6JRWK=
NCI-H2342 NUjrVHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjVU3NkUUN3ME23MlY{KG6P Ml[4V2FPT0WU
OVCAR-8 NFXmW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwOTDuUS=> NX\TWoJNW0GQR1XS
TE-8 NFW5d2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXBTWM2OD16IH7N MX3TRW5ITVJ?
ETK-1 NV7FVZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvTe5JoUUN3ME24MlA5KG6P M4W0PHNCVkeHUh?=
HAL-01 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTGOXBFUUN3ME24MlIhdk1? NX7PZWJLW0GQR1XS
KYSE-150 M1jKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWiyXnVVUUN3ME24MlQ4KG6P Mo\nV2FPT0WU
NCI-H810 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jCVGlEPTB;OD61OkBvVQ>? M4m0U3NCVkeHUh?=
ONS-76 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vXXGlEPTB;OD62PEBvVQ>? Moj2V2FPT0WU
NMC-G1 NEP3fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIji[3BKSzVyPUiuO|Yhdk1? MX;TRW5ITVJ?
C3A MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThwOESgcm0> MV\TRW5ITVJ?
PA-1 NEnLRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRThwOUmgcm0> MoD4V2FPT0WU
SH-4 NVTrWG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHaTWM2OD17LkCyJI5O NFqxeWZUSU6JRWK=
EFO-27 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rwXWlEPTB;OT6wOUBvVQ>? NUSyemVOW0GQR1XS
CAPAN-1 NV7GeHU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFV2RSUUN3ME25MlI{KG6P M4nLeHNCVkeHUh?=
DU-145 NWDpfI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XmfGlEPTB;OT6yPUBvVQ>? MWrTRW5ITVJ?
A101D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTlwM{egcm0> MkHNV2FPT0WU
ST486 NWfSW3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fHOmlEPTB;OT60NUBvVQ>? NGnoN3hUSU6JRWK=
NCI-H1437 NW[zTolVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHOTWM2OD17LkSyJI5O NY\lfJlkW0GQR1XS
HGC-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXIcGdKSzVyPUmuOkBvVQ>? MWTTRW5ITVJ?
8305C MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LqOGlEPTB;OT62OEBvVQ>? NX64[ldMW0GQR1XS
OCUB-M NHj4NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP0W3NnUUN3ME2xNE4xOyCwTR?= NGTnd|VUSU6JRWK=
COLO-679 NWrrO|ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTDWXBKSzVyPUGwMlA4KG6P Mn;rV2FPT0WU
Detroit562 NInpU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnJRYNrUUN3ME2xNE41OiCwTR?= NVW3PHpEW0GQR1XS
A204 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF74WmFKSzVyPUGxMlE3KG6P MmHVV2FPT0WU
NCI-H1734 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYOJBKSzVyPUGxMlI6KG6P M3nocnNCVkeHUh?=
MC-CAR Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Tw[2lEPTB;MUGuOVghdk1? M3jWPHNCVkeHUh?=
NCI-H2170 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSyTWM2OD1zMT65O{BvVQ>? MlPoV2FPT0WU
NCI-SNU-5 NVm5UJZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnOdZA1UUN3ME2xNk4yOyCwTR?= Mn\4V2FPT0WU
HCE-T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHMTWM2OD1zMj60NkBvVQ>? M3jEeXNCVkeHUh?=
KYSE-180 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF{LkixJI5O MXnTRW5ITVJ?
C8166 M2LyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLLTWM2OD1zMz6wPEBvVQ>? NXzNN2d{W0GQR1XS
NCI-H460 NYfTOHN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G1[WlEPTB;MUOuOVQhdk1? NX3EbYk4W0GQR1XS
SNU-449 NGDXNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K3eWlEPTB;MUOuO|chdk1? NYjyb4xPW0GQR1XS
MDA-MB-468 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0WoxrUUN3ME2xOE4yOiCwTR?= M2Dt[nNCVkeHUh?=
COR-L23 NHLpXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rPSWlEPTB;MUSuNVMhdk1? MoXqV2FPT0WU
CTV-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDTTWM2OD1zND6xOEBvVQ>? MXPTRW5ITVJ?
BL-41 NHSwboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32zcWlEPTB;MUSuN|chdk1? MYjTRW5ITVJ?
IGR-1 M4qzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\DUJo6UUN3ME2xOE41OiCwTR?= MlLkV2FPT0WU
TK10 M3jyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSxd25KSzVyPUG0MlQ6KG6P MoK3V2FPT0WU
REH MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF2LkWxJI5O M1fXfnNCVkeHUh?=
LU-139 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF2LkW5JI5O MmO2V2FPT0WU
KP-N-YS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLrcIFDUUN3ME2xOE46PyCwTR?= NHnIbXZUSU6JRWK=
PANC-10-05 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XSN2lEPTB;MUWuN|ghdk1? M4HOO3NCVkeHUh?=
HL-60 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fjTmlEPTB;MUWuOlkhdk1? M{fId3NCVkeHUh?=
T84 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\BTWM2OD1zNT65OkBvVQ>? MYXTRW5ITVJ?
RPMI-8226 NGHucIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DVRmlEPTB;MU[uNFIhdk1? NH;zRmNUSU6JRWK=
UM-UC-3 NGLxVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF4LkG2JI5O NVLCfG9RW0GQR1XS
TE-10 M17hcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP2Wo9SUUN3ME2xOk4zOSCwTR?= M{i5bHNCVkeHUh?=
CAL-148 NVPSWZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Nc5A3UUN3ME2xO{4zOyCwTR?= MVPTRW5ITVJ?
BV-173 NYTrZlNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7QbINWUUN3ME2xO{4zPyCwTR?= M{CyNnNCVkeHUh?=
Calu-3 M4\SZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjiXXVVUUN3ME2xO{4zQSCwTR?= Moe5V2FPT0WU
RPMI-2650 NF;vWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDKTWM2OD1zNz61PUBvVQ>? M{PUTHNCVkeHUh?=
MKN45 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLFTWM2OD1zNz63N{BvVQ>? NILhWnlUSU6JRWK=
NUGC-3 NGXBbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHjTWM2OD1zOD6zOEBvVQ>? NX22bXNRW0GQR1XS
NCI-H520 NYnjTnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf1TWM2OD1zOD63O{BvVQ>? M2r3U3NCVkeHUh?=
CCRF-CEM MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmyPWV7UUN3ME2xPE45PSCwTR?= M{XaPHNCVkeHUh?=
NCI-H2405 NULJSFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTTTWM2OD1zOT6xJI5O NXfsSlY4W0GQR1XS
ES7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF7Lke2JI5O NIPMVZFUSU6JRWK=
BPH-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXyTWM2OD1{MD6yPEBvVQ>? MmfyV2FPT0WU
SAS MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO0TWM2OD1{MD61JI5O NIrFPGRUSU6JRWK=
HuCCT1 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlztTWM2OD1{MD61PEBvVQ>? M1S3W3NCVkeHUh?=
LOUCY M1fsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHjSVlKSzVyPUKwMlY3KG6P MnHHV2FPT0WU
NCI-H292 MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWwTWM2OD1{MD63PUBvVQ>? M1;pVHNCVkeHUh?=
G-361 M3TaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu5TWM2OD1{MT6wO{BvVQ>? NFPlblRUSU6JRWK=
M059J MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITGW2pKSzVyPUKxMlA5KG6P M1PpZXNCVkeHUh?=
NCI-H1651 NXPOS41kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjsTWM2OD1{MT6xNUBvVQ>? NGTDRnJUSU6JRWK=
KALS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\5R4Z[UUN3ME2yNU4{QSCwTR?= M2e0PHNCVkeHUh?=
DJM-1 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjqd4xKSzVyPUKxMlU6KG6P MVnTRW5ITVJ?
AU565 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJzLkizJI5O MlPlV2FPT0WU
HCC38 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJzLkm1JI5O MkTPV2FPT0WU
U251 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfRWopFUUN3ME2yNk4zPyCwTR?= MlfsV2FPT0WU
ABC-1 MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPCTWM2OD1{Mj62OUBvVQ>? Mo\kV2FPT0WU
SK-NEP-1 M3PhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fPOWlEPTB;MkKuPVMhdk1? NVvhVG5UW0GQR1XS
CESS Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nHTGlEPTB;MkOuNVkhdk1? M1jLeXNCVkeHUh?=
MIA-PaCa-2 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DLR2lEPTB;MkOuN|Yhdk1? Mlj0V2FPT0WU
SUP-T1 NXzUbFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvKPWhKSzVyPUKzMlQ4KG6P MoK1V2FPT0WU
L-428 M2jGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfCfYxKSzVyPUKzMlYzKG6P NEnSb3VUSU6JRWK=
SW954 NVjCOpN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u3eWlEPTB;MkOuOlghdk1? M{DKXnNCVkeHUh?=
HO-1-N-1 NIfPPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ|Lke3JI5O NX76cmZRW0GQR1XS
CHP-126 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzwcmtmUUN3ME2yOE4yPCCwTR?= MmfUV2FPT0WU
HMV-II NYjXVWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ2LkO0JI5O Mkf5V2FPT0WU
NB10 NWn2e4JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ2LkO3JI5O NFzyfWdUSU6JRWK=
A172 NEXhc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17YXGlEPTB;MkSuO|Ehdk1? MUXTRW5ITVJ?
MONO-MAC-6 NF24UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvsTWM2OD1{ND64OEBvVQ>? NILyVVRUSU6JRWK=
NCI-H1650 M1y4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ3LkSgcm0> M1P1SXNCVkeHUh?=
NH-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3jTYNKSzVyPUK1MlUhdk1? MnfQV2FPT0WU
ML-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jYeGlEPTB;MkWuO|Qhdk1? NYnLd2plW0GQR1XS
MZ2-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P4SWlEPTB;Mk[uNlIhdk1? NELkNHZUSU6JRWK=
COLO-684 M{XNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmzTWM2OD1{Nj60NUBvVQ>? MV3TRW5ITVJ?
HuP-T4 M37iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfIUHpKSzVyPUK3MlMhdk1? NIj2UWpUSU6JRWK=
SW837 NELGW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnhTWlKSzVyPUK3MlYzKG6P M{KwWXNCVkeHUh?=
MDA-MB-231 NHT1XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LTUmlEPTB;MkeuO|ghdk1? NUezUZVFW0GQR1XS
KYSE-140 M4Tscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ5LkmxJI5O M4jNS3NCVkeHUh?=
NOMO-1 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1eydWlEPTB;MkiuOlghdk1? MXTTRW5ITVJ?
GP5d MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[yXGlEPTB;MkiuO|Ihdk1? MlrKV2FPT0WU
COR-L105 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW1dVVUUUN3ME2yPU41OiCwTR?= M3nzOHNCVkeHUh?=
LS-411N M2njR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKzdYlKSzVyPUK5Mlg5KG6P NILWV|RUSU6JRWK=
NY M2jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjFTWM2OD1|MD6xPEBvVQ>? M1Xz[3NCVkeHUh?=
NCI-H2030 NHfEW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnTTlNnUUN3ME2zNE41PSCwTR?= NXzIe2VlW0GQR1XS
CCF-STTG1 NUH6VVl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvT5dKSzVyPUOxMlQzKG6P MVLTRW5ITVJ?
NCI-H1703 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLzfJVKSzVyPUOxMlc5KG6P NIrGb4RUSU6JRWK=
TUR MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TGfGlEPTB;M{KuNFMhdk1? NEO5bmxUSU6JRWK=
NOS-1 M2H6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[5TWM2OD1|Mj60OEBvVQ>? MV3TRW5ITVJ?
A2058 NFnMT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojiTWM2OD1|Mj64N{BvVQ>? MUPTRW5ITVJ?
LCLC-103H NH[5[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD1|Mz6yOUBvVQ>? M4DHenNCVkeHUh?=
NCI-H510A M4CyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXjTWM2OD1|Mz6yO{BvVQ>? MYXTRW5ITVJ?
BC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO2TWM2OD1|Mz63O{BvVQ>? MoriV2FPT0WU
SK-CO-1 M3\1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXEUYh5UUN3ME2zOE4xOSCwTR?= MmfjV2FPT0WU
A673 NIK5TGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN2LkG3JI5O NEHRZ3RUSU6JRWK=
VM-CUB-1 NUDtUFgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHHTWM2OD1|ND62PUBvVQ>? NWTRU4NpW0GQR1XS
HH NUXUZoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrRbJRKSzVyPUO1MlA3KG6P NYf6VFhiW0GQR1XS
CAL-27 NEnMdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7tTmhKSzVyPUO1MlE3KG6P M4S0RXNCVkeHUh?=
NEC8 NFTOcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDYOlNKSzVyPUO1MlM4KG6P MlHWV2FPT0WU
BxPC-3 NUjhdHRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TDfGlEPTB;M{[uPVEhdk1? MVvTRW5ITVJ?
SNB75 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjQZYZqUUN3ME2zO{4zPCCwTR?= NHW5RY5USU6JRWK=
NB13 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;xOmJKSzVyPUO4MlI{KG6P M1OwZXNCVkeHUh?=
SK-OV-3 NG[2TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD1|OD63OEBvVQ>? M{\ZUXNCVkeHUh?=
ME-180 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\DOlVKSzVyPUO4Mlghdk1? NV\3T|RWW0GQR1XS
JiyoyeP-2003 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fzVmlEPTB;M{muN|ghdk1? MmLHV2FPT0WU
LU-134-A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPyTWM2OD12MD6wNkBvVQ>? M3zhXHNCVkeHUh?=
LS-123 M4TiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrodmdKSzVyPUSwMlI5KG6P NVW2NIo5W0GQR1XS
COLO-800 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHSdJdKSzVyPUSwMlU3KG6P Ml:4V2FPT0WU
LB831-BLC NYC2O4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRzLki1JI5O Mlj1V2FPT0WU
NCI-H747 M1vwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jTXmlEPTB;NEKuNlghdk1? M3fvWXNCVkeHUh?=
MZ7-mel M1HROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXsNHpKSzVyPUSyMlY3KG6P NHvn[YlUSU6JRWK=
GT3TKB M2Gx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle2TWM2OD12Mj63NkBvVQ>? NXXVRYZCW0GQR1XS
MOLT-16 M{TJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nmN2lEPTB;NEOuNFUhdk1? NU\MUYM4W0GQR1XS
23132-87 NESxdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\UNGNuUUN3ME20N{4xPSCwTR?= M4nNTHNCVkeHUh?=
PF-382 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7FW2t7UUN3ME20OE4zOiCwTR?= MVPTRW5ITVJ?
ES3 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHQTWM2OD12ND62JI5O M3XFO3NCVkeHUh?=
SW756 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTVfGo1UUN3ME20OU4yPCCwTR?= M1nCeHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 15 mg/mL (56.99 mM)
Water 14 mg/mL warmed (53.19 mM)
Ethanol <1 mg/mL
In vivo water warming 14mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID